While are biopharmaceutical companies after Hanmi Pharm?
While the biopharmaceutical industry has attracted high interests as the Hanmi Pharm’s technology transfers have been on everyone’s lips, a report was out from the securities industry, analyzing biopharmaceutical companies having noticeable pipelines in 2016.
On the 4th, Daewoo Securities select...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
